IP Library Granted Patent US 9,970,028
Granted Patent B2
US 9,970,028 · App. 14/990,300 · Granted May 15, 2018

Targeted genomic modification with partially single-stranded donor molecules

Inventors: Gregory J. Cost (Berkeley, CA); Dmitry M. Guschin (Seoul, KR); Fyodor Urnov (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/902C12N9/22C12N15/907C07K2319/80C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,970,028
App. No.
14/990,300
Granted
May 15, 2018
Kind
B2
Abstract

Disclosed herein are donor molecules comprising single-stranded complementary regions flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.

Claims (19)

1. A mammalian cell comprising:

a genome comprising a double-stranded break with single-stranded overhangs;

a non-naturally occurring nuclease comprising a DNA-binding molecule that binds to a target site of at least 9 nucleotides in length and endonuclease cleavage domain, which nuclease is capable of generating the double-stranded break with single-stranded overhangs in the genome at the target site of interest; and

an exogenous linear donor nucleic acid molecule comprising a double-stranded exogenous sequence of interest having first and second ends and first and second single-stranded sequences of 4 to 10 nucleotides at the first and second ends of the double-stranded sequence,

wherein the first and second single-stranded sequences are 100% complementary to the single-stranded overhangs in the genome such that the exogenous linear donor sequence is capable of being directly integrated at the target site of interest by annealing of the complementary first and second-single stranded sequences and non-homologous end joining (NHEJ)-mediated targeted integration.

2. The cell of claim 1 , wherein the exogenous linear donor further comprises one or more phosphorothioate or phosphodiester bonds between one or more nucleic acids.

3. The cell of claim 1 , wherein one or more nucleic acids of the exogenous linear donor are methylated or comprise non-natural nucleotide analogs.

4. The cell of claim 1 , wherein the sequence of interest comprises a polynucleotide encoding a functional polypeptide.

5. The cell of claim 4 , wherein the polypeptide is selected from the group consisting of an antibody, an antigen, an enzyme, a growth factor, a receptor, a hormone, a lymphokine, a cytokine, and a reporter.

6. The cell of claim 1 , wherein the sequence of interest comprises a sequence encoding a functional RNA.

7. The cell of claim 1 , wherein the sequence of interest comprises an integration site.

8. A method of integrating a linear nucleic acid molecule in to the genome of a cell, the method comprising:

culturing the cell according to claim 1 under conditions such that the linear nucleic acid molecule is integrated at the site of the double-stranded break.

9. The method of claim 8 , wherein the linear nucleic acid molecule further comprises one or more phosphorothioate or phosphodiester bonds between one or more nucleic acids.

10. The method of claim 8 , wherein one or more nucleic acids are methylated or comprise non-natural nucleotide analogs.

11. The method of claim 8 , wherein the sequence of interest comprises a polynucleotide encoding a functional polypeptide.

12. The method of claim 11 , wherein the polypeptide is selected from the group consisting of an antibody, an antigen, an enzyme, a growth factor, a receptor, a hormone, a lymphokine, a cytokine, a reporter and combinations therefore.

13. The method of claim 8 , wherein the sequence of interest comprises a sequence encoding a functional RNA.

14. The method of claim 8 , wherein the sequence of interest comprises an integration site.

Assignments (1)
CHANGE OF NAME Recorded Feb 14, 2018
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 045338/0889 →
Continuity (4)
Continuation 12931760 · Feb 9, 2011
Provisional Application 61337756 · Feb 9, 2010
Provisional Application 61342934 · Apr 21, 2010
Related Publication 20160145644A1 · May 26, 2016